Compare Biogen Inc (BIIB) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Nokia Corp — how do they compare? Biogen Inc trades at $192.49 (market cap $28.34B), while Nokia Corp trades at $12.04 (market cap $65.32B). The key difference: Nokia Corp is far larger — about 2.3× Biogen Inc's market cap, and Nokia Corp pays a 1.4% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | NOK | |
|---|---|---|
Market Cap | $28.34B | $65.32B |
Sector | Health | Technology |
52-Week High | $216.63 | $16.83 |
52-Week Low | $122.68 | $4.05 |
Enterprise Value | $30.62B | $62.14B |
Dividend Yield | — | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Nokia (NOK) trades at $11.675, down 6.04% today amid a broader technical pullback despite strong AI-driven momentum. The stock has surged over 100% YTD on AI infrastructure partnerships, including a $1 billion deal with Nvidia. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beat estimates. Valuation metrics appear elevated with a P/E of 73.32, while profitability remains modest with a 3.98% net margin. Cash flow trends show volatility, with 2025 net cash flow negative at -$1.16 billion.
Nokia's AI transformation presents significant upside potential with analyst consensus target of $18.00 (54% upside), but high valuation and execution risks warrant caution. The company's pivot to AI networking infrastructure is gaining traction, though supply constraints and heavy R&D spending could pressure near-term profitability. Technical indicators suggest near-term bearish pressure with key support at $11.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
